SU-F-T-160: Commissioning of a Single-Room Double-Scattering Proton Therapy System

Authors


Abstract

Purpose:

To report the detailed commissioning experience for a compact double-scattering Mevion S250 proton therapy system at a University Cancer Center site.

Methods:

The commissioning of the proton therapy system mainly consisted of ensuring integrity of mechanical and imaging system, beam data collection, and commissioning of a treatment planning system (TPS). First, mechanical alignment and imaging were tested including safety, interlocks, positional accuracy of couch and gantry, image quality, mechanical and imaging isocenter and so on. Second, extensive beam data (outputs, PDDs, and profiles) were collected and analyzed through effective sampling of range (R) and modulation width (M) from 24 beam options. Three different output (cGy/MU) prediction models were also commissioned as primary and secondary MU calculation tool. Third, the Varian Eclipse TPS was commissioned through five sets of data collections (in-water Bragg peak scans, in-air longitudinal fluence scans, in-air lateral profiles, in-air half-beam profiles, and an HU-to-stopping-power conversion curve) and accuracy of TPS calculation was tested using in-water scans and dose measurements with a 2D array detector with block and range compensator. Finally, an anthropomorphic phantom was scanned and heterogeneity effects were tested by inserting radiochromic films in the phantom and PET activation scans for range verification in conjunction with end-to-end test.

Results:

Beam characteristics agreed well with the vendor specifications; however, minor mismatches in R and M were found in some measurements during the beam data collection. These were reflected into the TPS commissioning such that the TPS could accurately predict the R and M within tolerance levels. The output models had a good agreement with measured outputs (<3% error). The end-to-end test using the film and PET showed reasonably the TPS predicted dose, R and M in heterogeneous medium.

Conclusion:

The proton therapy system was successfully commissioned and was released for clinical use.

Ancillary